Richard B. Kim
YOU?
Author Swipe
View article: An Update to the Clinical Pharmacogenetics Implementation Consortium ( <scp>CPIC</scp> ) <i>SLCO1B1</i> Allele Functionality Table Leveraging Evidence from Participants of Predominantly Sub‐Saharan African Ancestry
An Update to the Clinical Pharmacogenetics Implementation Consortium ( <span>CPIC</span> ) <i>SLCO1B1</i> Allele Functionality Table Leveraging Evidence from Participants of Predominantly Sub‐Saharan African Ancestry Open
The Clinical Pharmacogenetics Implementation Consortium (CPIC) has formally updated the SLCO1B1 allele functionality table based on new evidence. Notably, the alleles studied ( SLCO1B1 *9 , *31 , *41 ) are enriched in the genomes of patien…
View article: <scp>IL23</scp> Receptor Polymorphism Is a Predictor of Anti‐Tumour Necrosis Factor‐α‐Induced Paradoxical Psoriasis in Inflammatory Bowel Disease
<span>IL23</span> Receptor Polymorphism Is a Predictor of Anti‐Tumour Necrosis Factor‐α‐Induced Paradoxical Psoriasis in Inflammatory Bowel Disease Open
Background Paradoxical psoriasis (PP) is an adverse drug reaction associated with anti‐tumour necrosis factor (TNF)‐α therapy leading to disfiguring skin lesions that may impact an individual's quality of life and affect their inflammatory…
View article: Deciphering the Relative Contribution of <scp>CYP3A4</scp> Versus P‐Glycoprotein for the Shared Substrate Cyclosporine—Commentary on Lown <i>et al</i>.
Deciphering the Relative Contribution of <span>CYP3A4</span> Versus P‐Glycoprotein for the Shared Substrate Cyclosporine—Commentary on Lown <i>et al</i>. Open
The oral bioavailability of cyclosporine, a substrate of both CYP3A4 and P‐glycoprotein, is subject to large inter‐individual variability, which requires frequent monitoring of plasma concentrations. In 1997, the study by Lown et al . show…
View article: Severe myelosuppression and alopecia after thiopurine initiation in a patient with <i>NUDT15</i> deficiency
Severe myelosuppression and alopecia after thiopurine initiation in a patient with <i>NUDT15</i> deficiency Open
Thiopurines are a class of immunosuppressant and antineoplastic agents. They are widely used in the treatment of inflammatory bowel disease, haematological malignancies and autoimmune diseases, but can cause significant toxicity. Inherited…
View article: Enhancing Rural Healthcare Accessibility: A Model for Pharmacogenomics Adoption via an Outreach-Focused Integration Strategy
Enhancing Rural Healthcare Accessibility: A Model for Pharmacogenomics Adoption via an Outreach-Focused Integration Strategy Open
Background/Objectives: Pharmacogenomics is an emerging field in precision medicine that aims to improve patient outcomes by tailoring drug selection and dosage to an individual’s genetic makeup. However, patients in rural communities often…
View article: Co‐prescription of low‐dose methotrexate and trimethoprim‐sulfamethoxazole and the 30‐day risk of death among older adults: A cohort study
Co‐prescription of low‐dose methotrexate and trimethoprim‐sulfamethoxazole and the 30‐day risk of death among older adults: A cohort study Open
Aims The aim of this study was to characterize the risk of death in older adults co‐prescribed low‐dose methotrexate and TMP‐SMX vs . low‐dose methotrexate and a cephalosporin. Methods We conducted a retrospective, population‐based, new‐us…
View article: SLCO1B1 variants in a patient of African ancestry presenting with rosuvastatin‐induced rhabdomyolysis: A case report
SLCO1B1 variants in a patient of African ancestry presenting with rosuvastatin‐induced rhabdomyolysis: A case report Open
We report a case of an adult woman of African ancestry who was hospitalized with statin induced‐ rhabdomyolysis. The patient presented to the emergency room with a 2‐week history of worsening muscle pain, nausea, vomiting and low oral inta…
View article: Solanidine Metabolites as Diet‐Derived Biomarkers of <scp>CYP2D6</scp>‐Mediated Tamoxifen Metabolism in Breast Cancer Patients
Solanidine Metabolites as Diet‐Derived Biomarkers of <span>CYP2D6</span>‐Mediated Tamoxifen Metabolism in Breast Cancer Patients Open
Tamoxifen is an important antiestrogen for the treatment of hormone receptor‐positive breast cancer and undergoes bioactivation by CYP2D6 to its active metabolite endoxifen. Genetic variation in CYP2D6 has been linked to endoxifen levels d…
View article: Thirty‐day risk of digoxin toxicity among older adults co‐prescribed trimethoprim‐sulfamethoxazole versus amoxicillin: A population‐based cohort study
Thirty‐day risk of digoxin toxicity among older adults co‐prescribed trimethoprim‐sulfamethoxazole versus amoxicillin: A population‐based cohort study Open
Importance Trimethoprim‐sulfamethoxazole (TMP‐SMX) may increase digoxin concentration, a medication with a narrow therapeutic index. Small changes in digoxin concentration could predispose individuals to the risk of toxicity. Objective To …
View article: Impact of CYP2C19 metabolizer status on esophageal mucosal inflammation, acid exposure, and motility among patients on chronic proton-pump inhibitor therapy with refractory symptoms of gastroesophageal reflux disease
Impact of CYP2C19 metabolizer status on esophageal mucosal inflammation, acid exposure, and motility among patients on chronic proton-pump inhibitor therapy with refractory symptoms of gastroesophageal reflux disease Open
Background The extent of disease severity remains unclear among CYP2C19 rapid and ultra-rapid metabolizers with refractory symptoms of gastroesophageal reflux disease (GERD) on chronic proton-pump inhibitors (PPIs). Aims To determine the i…
View article: High-Throughput Computing to Automate Population-Based Studies to Detect the 30-Day Risk of Adverse Outcomes After New Outpatient Medication Use in Older Adults with Chronic Kidney Disease: A Clinical Research Protocol
High-Throughput Computing to Automate Population-Based Studies to Detect the 30-Day Risk of Adverse Outcomes After New Outpatient Medication Use in Older Adults with Chronic Kidney Disease: A Clinical Research Protocol Open
Background: Safety issues are detected in about one third of prescription drugs in the years following regulatory agency approval. Older adults, especially those with chronic kidney disease, are at particular risk of adverse reactions to p…
View article: Patients’ Experiences of a Precision Medicine Clinic
Patients’ Experiences of a Precision Medicine Clinic Open
The purpose of this study is to provide an overview of patients’ experiences using a precision medicine (PM) clinic that conducts pharmacogenomics-based (PGx) testing for adverse drug reactions. The study aimed to identify the features of …
View article: Low-Dose Methotrexate and Serious Adverse Events Among Older Adults With Chronic Kidney Disease
Low-Dose Methotrexate and Serious Adverse Events Among Older Adults With Chronic Kidney Disease Open
Importance Low-dose methotrexate is used to treat rheumatoid arthritis and psoriasis. Due to its kidney elimination, better evidence is needed to inform its safety in adults with chronic kidney disease (CKD). Objectives To compare the 90-d…
View article: Genetic Variation in miR-27a Is Associated with Fluoropyrimidine-Associated Toxicity in Patients with Dihydropyrimidine Dehydrogenase Variants after Genotype-Guided Dose Reduction
Genetic Variation in miR-27a Is Associated with Fluoropyrimidine-Associated Toxicity in Patients with Dihydropyrimidine Dehydrogenase Variants after Genotype-Guided Dose Reduction Open
Dihydropyrimidine dehydrogenase (DPYD) is the rate-limiting enzyme involved in the metabolism of fluoropyrimidine-based chemotherapy. However, single-nucleotide variants (SNVs) in DPYD only partially explain fluoropyrimidine-induced toxici…
View article: Adverse events with quetiapine and clarithromycin coprescription: A population‐based retrospective cohort study
Adverse events with quetiapine and clarithromycin coprescription: A population‐based retrospective cohort study Open
Background and Aims Quetiapine is an atypical antipsychotic predominantly metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme. We studied the risk of adverse events following coprescription of clarithromycin (a strong CYP3A4 inhibitor) …
View article: Expression and localization of efflux drug transporters P-glycoprotein and breast cancer resistance protein (BCRP) in adult human pancreatic islet alpha and beta cells
Expression and localization of efflux drug transporters P-glycoprotein and breast cancer resistance protein (BCRP) in adult human pancreatic islet alpha and beta cells Open
P-glycoprotein (P-gp, ABCB1) and breast cancer resistance protein (BCRP, ABCG2) are clinically important efflux transporters of the ATP-binding cassette (ABC) family of transporters, widely recognized for their broad substrate specificity …
View article: Data from Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance
Data from Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance Open
The antimicrotubular agent docetaxel is a widely used chemotherapeutic drug for the treatment of multiple solid tumors and is predominantly dependent on hepatic disposition. In this study, we evaluated drug uptake transporters capable of t…
View article: Supplementary Table 2 from Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance
Supplementary Table 2 from Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance Open
SLCO1B3 Variants
View article: Supplementary Table 1 from Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance
Supplementary Table 1 from Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance Open
SLCO1B1 Variants
View article: Data from Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance
Data from Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance Open
The antimicrotubular agent docetaxel is a widely used chemotherapeutic drug for the treatment of multiple solid tumors and is predominantly dependent on hepatic disposition. In this study, we evaluated drug uptake transporters capable of t…
View article: Supplementary Table 1 from Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance
Supplementary Table 1 from Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance Open
SLCO1B1 Variants
View article: Supplementary Table 2 from Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance
Supplementary Table 2 from Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance Open
SLCO1B3 Variants
View article: Supplementary Table 1 from Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity
Supplementary Table 1 from Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity Open
Supplementary Table 1 from Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity
View article: Data from Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity
Data from Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity Open
Thiopurines are effective immunosuppressants and anticancer agents, but intracellular accumulation of their active metabolites (6-thioguanine nucleotides, 6-TGN) causes dose-limiting hematopoietic toxicity. Thiopurine S-methyltransf…
View article: Supplementary Figure 1 from Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity
Supplementary Figure 1 from Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity Open
Supplementary Figure 1 from Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity
View article: Supplementary Figure 1 from Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity
Supplementary Figure 1 from Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity Open
Supplementary Figure 1 from Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity
View article: Supplementary Table 1 from Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity
Supplementary Table 1 from Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity Open
Supplementary Table 1 from Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity
View article: Data from Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity
Data from Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity Open
Thiopurines are effective immunosuppressants and anticancer agents, but intracellular accumulation of their active metabolites (6-thioguanine nucleotides, 6-TGN) causes dose-limiting hematopoietic toxicity. Thiopurine S-methyltransf…
View article: Thiopurine Methyltransferase Intermediate Metabolizer Status and Thiopurine‐Associated Toxicity During Maintenance Therapy in Childhood Acute Lymphoblastic Leukemia
Thiopurine Methyltransferase Intermediate Metabolizer Status and Thiopurine‐Associated Toxicity During Maintenance Therapy in Childhood Acute Lymphoblastic Leukemia Open
Mercaptopurine is a cornerstone of maintenance chemotherapy in childhood acute lymphoblastic leukemia (ALL). Its cytotoxic effects are mediated by 6‐thioguanine nucleotides (TGNs) incorporation into lymphocyte DNA. Thiopurine methyltransfe…
View article: DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation
DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation Open
Fluoropyrimidine chemotherapy is associated with interpatient variability in toxicity. A major contributor to unpredictable and severe toxicity relates to single nucleotide variation (SNV) in dihydropyrimidine dehydrogenase (DPYD), the rat…